Showing 5451-5460 of 20466 results for "".
- Revolutionizing Lung Cancer Diagnosis: The Role of Robotic Navigational Bronchoscopyhttps://reachmd.com/news/revolutionizing-lung-cancer-diagnosis-the-role-of-robotic-navigational-bronchoscopy/2483449/As robotic navigational bronchoscopy steadily progresses, it is advancing lung cancer diagnosis, offering more consistent navigation to small, peripheral nodules under CT-guided workflows. In clinical practice, its use is considered within evolving ACCP/ATS/NCCN recommendations for evaluati
- Advancements in Breast Cancer Management: Lymphedema and Chemotherapy Successhttps://reachmd.com/news/advancements-in-breast-cancer-management-lymphedema-and-chemotherapy-success/2483461/The intricate landscape of breast cancer treatment continues to challenge and inspire advancements focused on elevating patient care. As clinicians strive to balance clinical efficacy with quality of life, new strategies in both surgical and chemotherapeutic domains are reshaping th
- The Fragile Connection: Microplastics and Bone Healthhttps://reachmd.com/news/the-fragile-connection-microplastics-and-bone-health/2483447/Microplastics are steadily entering human exposure pathways and are reshaping how clinicians think about bone health, tightening the connection between environmental load and the biology of bone remodeling. Building from that exposure signal, systemic inflammation em
- The Economic Toll of Climate Change: Redefining Public Health Policieshttps://reachmd.com/news/the-economic-toll-of-climate-change-redefining-public-health-policies/2483450/Climate change is intensifying immediate trade-offs in public health policy, as budgets are being stretched between near-term clinical services and investments that protect people from heat and poor air quality. As these losses mount, policymakers are weighing what t
- Rethinking Risk: Navigating the Complexities of GG1 Prostate Cancerhttps://reachmd.com/news/rethinking-risk-navigating-the-complexities-of-gg1-prostate-cancer/2483467/Prostate cancer poses a common clinical challenge in urology, particularly around accurately assessing risk in Grade Group 1 (GG1) cases. The narrative begins with a practical realization: reevaluating risk in GG1 prostate cancer may reduce overtreatment and support more individuali
- Not Just a Headache: Migraine Across Women’s Lifespan at WHAV 2025https://reachmd.com/news/not-just-a-headache-migraine-across-womens-lifespan-at-whav-2025/2483469/New York, NY — At the 2025 Women’s Health Annual Visit (WHAV), neurologists Dr. Jelena Pavlović (Albert Einstein College of Medicine) and Dr. Amaal Starling (Mayo Clinic) delivered a comprehensive session on migraine, highlighting its disproportionate impact on women, the influen
- Evaluating COVID Vaccine Safety for Pregnant Women and Children: Latest Findingshttps://reachmd.com/news/evaluating-covid-vaccine-safety-for-pregnant-women-and-children-latest-findings/2483454/Vaccination efforts in pregnancy and pediatric populations are underpinned by robust studies, supporting safety while addressing lingering concerns. Surveillance and education remain key components in increasing vaccine uptake among hesitant groups. Recent studies af
- Unlocking Asthma Remission: The Role of FeNO in Small Airwayshttps://reachmd.com/news/unlocking-asthma-remission-the-role-of-feno-in-small-airways/2483442/The clinical importance of small airways in asthma management is becoming ever clear, as reflected in contemporary guideline summaries, with new insights revealing their role in achieving remission-like control in selected patients. Innovative biomarkers such as Fractional Exhaled Nitric Ox
- Harnessing Exercise: A New Frontier in Reducing Drug Cravingshttps://reachmd.com/news/harnessing-exercise-a-new-frontier-in-reducing-drug-cravings/2483435/Amid rising pressures from substance use disorders, clinicians are increasingly considering exercise interventions not merely as an adjunct to treatment but as a component of comprehensive care. Emerging evidence from small trials and observational studies suggests that
- FDA Approves Topical Ruxolitinib for AD in Children Aged 2 and Uphttps://reachmd.com/news/fda-approves-topical-ruxolitinib-for-ad-in-children-aged-2-and-up/2483445/The US Food and Drug Administration (FDA) has approved ruxolitinib cream 1.5% (Opzelura) for the short-term and non-continuous chronic treatment of mild-to-moderate atopic dermatitis (AD) in non-immunocompromised children ages 2 and older whose disease is inadequate